Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
129 pending office actions • 50 art units • 111 examiners • 0 of 129 (0%) have an AI response strategy ready • 118 patents granted in the last 365 days
Amgen Inc. has 130 pending office actions in Biotechnology & Pharmaceuticals. The portfolio reaches 108 distinct examiners across 49 distinct art units. This is a large and widely distributed prosecution workload, with extensive examiner coverage and repeated presence in multiple technical examination groups.
SKELDING, ZACHARY S is the busiest examiner, with 4 pending matters. The largest identified examiner grouping is limited compared with the overall portfolio, so examiner-specific tactics will apply to only a portion of the work. Counsel should combine centralized biotechnology claim strategy with detailed matter-level preparation across the art units.
Based on the USPTO statutory response window for each pending office action. 33 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 33 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §101 + other | 10 (8%) |
| §103 only | 29 (22%) |
| §102 only | 5 (4%) |
| §112 only | 12 (9%) |
| Double-patenting only | 4 (3%) |
| Double-patenting + other | 24 (19%) |
| Multi-statute (no §101) | 40 (31%) |
| No statute on record | 4 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKELDING, ZACHARY S | 4 | 59.8% | +41.1% |
| BRISTOL, LYNN ANNE | 3 | 63.4% | +39.8% |
| DUFFY, BRADLEY | 3 | 54.4% | +46.0% |
| TECCO, ANDREW M | 2 | 65.5% | +24.6% |
| BOUCHELLE, LAURA A | 2 | 80.2% | +10.3% |
| PATEL, SHEFALI DILIP | 2 | 58.1% | +27.7% |
| HALL, DEANNA K | 2 | 75.7% | +15.3% |
| SZPERKA, MICHAEL EDWARD | 2 | 62.6% | +37.5% |
| XU, XIAOYUN | 2 | 59.9% | +31.6% |
| KAUFMAN, CLAIRE M | 2 | 63.3% | +51.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17846310 | SYRINGES, ASSEMBLIES, AND METHODS OF MANUFACTURE | BOUCHELLE, LAURA A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18018389 | CELL CULTURE MEDIA AND METHODS OF MAKING AND USING THE SAME | VAN BUREN, LAUREN K | 153d overdue |
| 17775386 | Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules | SKELDING, ZACHARY S | 52d overdue |
| 18270581 | USE OF KRAS G12C INHIBITOR IN TREATING CANCERS | HASTINGS, ALISON AZAR | 23d overdue |
| 17436218 | IN VIVO REVERSIBILITY OF HIGH MOLECULAR WEIGHT SPECIES | FRITCHMAN, REBECCA M | 8d |
| 18266689 | DIFFUSION GRADIENT ASSAY FOR ANTI-CD3-CONTAINING MOLECULES | SPENCE, JENNIFER SUZANNE | 12d |
| 18038579 | ENANTIOSELECTIVE ALKENYLATION OF ALDEHYDES | MOORE, SUSANNA | 16d |
| 17036690 | DRUG DELIVERY DEVICE | LALONDE, ALEXANDRA ELIZABETH | 22d |
| 18026678 | METHODS OF PROCESSING A SAMPLE FOR PEPTIDE MAPPING ANALYSIS | ARMATO JR, DENNIS IGNATIUS | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042267 | ANTIGEN BINDING PROTEINS WITH NON-CANONICAL DISULFIDE IN FAB REGION | BRISTOL, LYNN ANNE | 93d overdue |
| 16586318 | CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS | SKELDING, ZACHARY S | 77d overdue |
| 17775386 | Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules | SKELDING, ZACHARY S | 52d overdue |
| 17775063 | ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES | DUFFY, BRADLEY | 45d overdue |
| 17921793 | PHARMACEUTICAL FORMULATION | KAUFMAN, CLAIRE M | 17d overdue |
| 18245004 | METHODS OF DETECTING ISOASPARTIC ACID | XU, XIAOYUN | 28d |
| 18962768 | AUTOMATED SYSTEMS AND METHODS FOR FOIL PACKAGING COMPONENTS | TECCO, ANDREW M | — |
| 18845286 | PACKAGING FOR DRUG DELIVERY DEVICE | TECCO, ANDREW M | — |
| Art Unit | Apps |
|---|---|
| 3783 | 24 |
| 1643 | 8 |
| 1641 | 8 |
| 1674 | 7 |
| 1644 | 6 |
| 1675 | 4 |
| 1642 | 4 |
| 1622 | 3 |
| 3731 | 3 |
| 1651 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19281019 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | SIMMONS, CHRIS E | 1622 | §112Other | Non-Final OA | 75d | Pending | Jul 25, 2025 |
| 19045308 | ROBOTIC SYSTEM FOR PERFORMING PATTERN RECOGNITION-BASED INSPECTION OF PHARMACEUTICAL CONTAINERS | RODRIGUEZ, JOSEPH C | 3653 | §103Other | Non-Final OA | — | Pending | Feb 04, 2025 |
| 18878828 | ANTI-PD-1 ANTIBODY FORMULATIONS | OGUNBIYI, OLUWATOSIN A | 1645 | §103§112 | Non-Final OA | — | Pending | Dec 24, 2024 |
| 18967331 | METHODS OF TREATING HEART FAILURE BY ADMINISTERING OMECAMTIV MECARBIL | COHEN, MICHAEL P | — | §112 | Non-Final OA | — | Pending | Dec 03, 2024 |
| 18962768 | AUTOMATED SYSTEMS AND METHODS FOR FOIL PACKAGING COMPONENTS | TECCO, ANDREW M | 3731 | §102§103 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18939822 | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | O DELL, DAVID K | 1621 | DP | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18855457 | COMPLEMENT-DEPENDENT CYTOTOXICITY METHODS | CURRENS, GRANT CARSON | 1651 | §103 | Non-Final OA | — | Pending | Oct 09, 2024 |
| 18853977 | SYSTEMS AND METHODS FOR REDUCING EXCESS RESOURCE USAGE | KESSLER, GREGORY AARON | 2197 | §101§102 | Non-Final OA | — | Pending | Oct 03, 2024 |
| 18853736 | Cancer Treatments Using MTA-Cooperative PRMT5 Inhibitors | MCKOY, QUINCY ANDRE | 1626 | §103§112DP | Non-Final OA | — | Pending | Oct 03, 2024 |
| 18845273 | OPTIMIZED TRANSFECTION PROTOCOL | CORDAS, EMILY ANN | 1632 | §103 | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18845286 | PACKAGING FOR DRUG DELIVERY DEVICE | TECCO, ANDREW M | 3731 | §102§103§112 | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18842194 | A PROCESS FOR PREPARING 4-METHYL-2-PROPAN-2-YL-PYRIDINE-3-CARBONITRILE | RAHMANI, NILOOFAR | 1691 | Other | Final Rejection | — | Pending | Aug 28, 2024 |
| 18807705 | MACHINE LEARNING (ML)-BASED SYSTEMS AND METHODS FOR PREDICTING DISEASE | EVANS, ASHLEY ELIZABETH | 3687 | §101§103 | Non-Final OA | 39d | Pending | Aug 16, 2024 |
| 18798878 | AFLIBERCEPT ATTRIBUTES AND METHODS OF CHARACTERIZING AND MODIFYING THEREOF | BORGEEST, CHRISTINA M | 1675 | §101§102§103§112 | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18789085 | DRUG DELIVERY DEVICE | BOUCHELLE, LAURA A | 3783 | §102§103Other | Non-Final OA | — | Pending | Jul 30, 2024 |
| 18832887 | SYNTHESIS OF A KIF18A INHIBITOR | OH, TAYLOR V | 1625 | §102§112 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18730353 | Crystalline Salt and Solvate Forms Of Murizatoclax (AMG 397) | DAHLIN, HEATHER RAQUEL | 1629 | §103§112DP | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18730357 | Crystalline Forms Of An MCL-1 Inhibitor | SAMSELL, RILLA MARIE | 1624 | §102§103§112 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18744036 | AUTOINJECTOR WITH SHOCK REDUCING ELEMENTS | MEDWAY, SCOTT J | 3783 | §102§103 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18719164 | METHODS FOR DESIGNING AND PERFORMING A VAPOR PHASE HYDROGEN PEROXIDE DECONTAMINATION CYCLE | HOERNER, PAUL ELLSWORTH | 1611 | §112 | Final Rejection | — | Pending | Jun 12, 2024 |
| 18674549 | INJECTION DEVICE FOR DRUG DELIVERY AND PACKAGING FOR THE INJECTION DEVICE | PATEL, SHEFALI DILIP | 3783 | §102§103 | Final Rejection | — | Pending | May 24, 2024 |
| 18712768 | STOPPER PLACEMENT IN A SYRINGE | SEIF, DARIUSH | 3731 | §102§103§112 | Non-Final OA | — | Pending | May 23, 2024 |
| 18710112 | PLUNGER ROD REMOVAL FORCE METHOD AND FIXTURE | PATEL, SHEFALI DILIP | 3783 | §102§103§112 | Non-Final OA | — | Pending | May 14, 2024 |
| 18645779 | CONTROLLABLE DRUG DELIVERY SYSTEM AND METHOD OF USE | HALL, DEANNA K | 3783 | §102§103 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18701723 | COMPOSITION AND METHODS FOR RECOMBINANT LENTIVIRAL PRODUCTION | PRONZATI, GINA | 1633 | §103§112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18698098 | FC-GAMMA RECEPTOR II BINDING AND GLYCAN CONTENT | EVANS, CHRISTOPHER RYAN | 1677 | §102§103§112 | Non-Final OA | — | Pending | Apr 03, 2024 |
| 18697770 | CHARACTERIZATION APPARATUS FOR DRUG DELIVERY DEVICES OR SUBCOMPONENTS THEREOF | NATH, SUMAN KUMAR | 2855 | §101 | Non-Final OA | — | Pending | Apr 02, 2024 |
| 18696946 | Heterocyclic Compounds and Methods of Use | CHAO, ALLEN | 1622 | §103DP | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18611364 | ST2 ANTIGEN BINDING PROTEINS | MCCOLLUM, ANDREA K | 1674 | §101§112Other | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18685037 | MYOPEPTIDES AND METHODS OF USE IN TREATING HEART FAILURE | CHERNYSHEV, OLGA N | 1675 | §112 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18684262 | METHODS COMPRISING THERAPEUTIC COMPOUNDS AND IN VITRO MAMMALIAN SKIN | CLARKE, TRENT R | 1651 | §101§103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18435746 | TIGIT AND CD112R BLOCKADE | GAO, ASHLEY HARTMAN | 1678 | §112 | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18681252 | ISOLATION OF THERAPEUTIC PROTEIN | HOLLAND, PAUL J | 1656 | §103 | Final Rejection | — | Pending | Feb 05, 2024 |
| 18291294 | STEREOSELECTIVE PREPARATION OF TRANS HALO CYCLOBUTANE | BAKSHI, PANCHAM | 1623 | §112 | Final Rejection | — | Pending | Jan 23, 2024 |
| 18571614 | Treatment of Cardiovascular Disease with TREM-1 Antigen Binding Proteins | PRIEST, JESSICA MARIE | 1642 | §112DP | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18538279 | ANTIBODY CONSTRUCTS FOR MSLN AND CD3 | BRISTOL, LYNN ANNE | 1643 | §112DP | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18535068 | FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME | LANDSMAN, ROBERT S | 1647 | Other | Final Rejection | 21d | Pending | Dec 11, 2023 |
| 18525039 | METHODS OF ANTIBODY PRODUCTION | NGUYEN, JOHN P | 1619 | §103 | Final Rejection | 70d | Pending | Nov 30, 2023 |
| 18564805 | DRUG DELIVERY DEVICES, FINGER-GRIP ELEMENTS, AND RELATED METHODS | DOUBRAVA, JOHN A | 3783 | §102 | Final Rejection | — | Pending | Nov 28, 2023 |
| 18561341 | FEEDBACK SYSTEM AND METHOD FOR A DRUG PRODUCT | CASILLASHERNANDEZ, OMAR | 2689 | §103 | Final Rejection | — | Pending | Nov 16, 2023 |
| 18289317 | DOSING REGIMEN FOR COMBINATION THERAPY TARGETING DLL3 AND PD-1 | DUTT, ADITI | 1675 | DP | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18288410 | ETELCALCETIDE FORMULATIONS | LEE, JIA-HAI | 1658 | §103§112DP | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18287593 | ANTI-TSLP ANTIBODY COMPOSITIONS AND USES THEREOF | MIDDLETON, DANAYA L | 1674 | §103§112DP | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18381745 | DUAL RECEPTOR ANTAGONISTIC ANTIGEN-BINDING PROTEINS AND USES THEREOF | LI, RUIXIANG | 1674 | Other | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18286702 | Automated Outlier Removal for Multivariate Modeling | BECK, LERON | 2487 | §103 | Final Rejection | — | Pending | Oct 12, 2023 |
| 18286242 | SYSTEMS AND METHODS TO EVALUATE INACTIVATION KINETICS OF A BIOLOGICAL INDICATOR | NEGIN, RUSSELL SCOTT | 1686 | §101§103 | Non-Final OA | — | Pending | Oct 10, 2023 |
| 18285125 | MAGEB2 BINDING CONSTRUCTS | JOHANSEN, PETER N. | 1644 | §112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18284590 | MODULATING PRODUCT QUALITY OF ASYMMETRIC MULTISPECIFIC ANTIBODIES THROUGH THE USE OF TEMPERATURE | AEDER, SEAN E | 1642 | §103§112 | Non-Final OA | — | Pending | Sep 28, 2023 |
| 18550650 | SOUND-DETECTION BASED INJECTION TIME MEASUREMENT SYSTEM FOR DRUG DELIVERY DEVICES | FREHE, WILLIAM R | 3783 | §102§103 | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18550645 | COMPONENT MATCHING DECISION SUPPORT TOOL | CARTER, CHRISTOPHER W | 2117 | §102 | Final Rejection | — | Pending | Sep 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmgen Inc. has 129 pending office actions as of October 2026, spread across 50 art units and 111 examiners.
Zachary S Skelding has the most, with 4 of Amgen Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
